Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Katharine H. D. Crawford(University of Washington), Adam S. Dingens(Fred Hutch Cancer Center), Rachel Eguia(Fred Hutch Cancer Center), Caitlin R. Wolf(University of Washington), Naomi Wilcox(University of Washington), Jennifer K. Logue(University of Washington), Kiel Shuey(University of Washington), Amanda M. Casto(University of Washington), Brooke Fiala(University of Washington), Samuel Wrenn(University of Washington), Deleah Pettie(University of Washington), Neil P. King(University of Washington), Alexander L. Greninger(University of Washington), Helen Y. Chu(University of Washington), Jesse D. Bloom(Howard Hughes Medical Institute)
The Journal of Infectious Diseases
September 28, 2020
Cited by 281Open Access
Full Text

Abstract

Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop neutralizing antibodies that target the viral spike protein. In this study, we quantified how levels of these antibodies change in the months after SARS-CoV-2 infection by examining longitudinal samples collected approximately 30-152 days after symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about 4-fold from 1 to 4 months after symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike protein or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.


Related Papers

No related papers found

Powered by citation graph analysis